Evidence map›Paper›PMID 41872305›Full record

ArticleScientific reports2026

The first limb-sparing use of histotripsy for canine osteosarcoma.

Elliana R Vickers, Lauren N Ruger, Alayna N Hay, Ny T C Luong, John S Kett, Summer Vander Kooi, Sheryl L Coutermarsh-Ott, Gregory B Daniel, Timothy J Ziemlewicz, Steven B Soliman and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elliana R VickersDepartment of Biomedical Engineering and Mechanics, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Lauren N RugerDepartment of Biomedical Engineering and Mechanics, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Alayna N HayVirginia Tech Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Roanoke, VA, USA.
Ny T C LuongVirginia Tech Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Roanoke, VA, USA.
John S KettDoctor of Veterinary Medicine Program, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, USA.
Summer Vander KooiSchool of Animal Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Sheryl L Coutermarsh-OttDepartment of Biomedical Sciences and Pathobiology, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Gregory B DanielDepartment of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, USA.
Timothy J ZiemlewiczDepartment of Radiology, University of Wisconsin, Madison, WI, USA.
Steven B SolimanDivision of Musculoskeletal Radiology, Department of Radiology, University of Michigan/Michigan Medicine, Ann Arbor, MI, USA.
Gunjan B MalhotraDivision of Musculoskeletal Radiology, Department of Radiology, University of Michigan/Michigan Medicine, Ann Arbor, MI, USA.
Adam D MaxwellDepartment of Biomedical Engineering and Mechanics, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Eli VlaisavljevichDepartment of Biomedical Engineering and Mechanics, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Joanne TuohyVirginia Tech Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Roanoke, VA, USA. jltuohy@vt.edu.

Funding

NCI NIH HHS 1F31CA294976-01NCI NIH HHS 1R01CA289288-01NIBIB NIH HHS 1R21EB030182-01
6 · The paper itself

Abstract

Osteosarcoma (OS) is a devastating primary bone cancer in dogs and humans. Histotripsy is a non-invasive ablation technique that mechanically destroys targeted tumor with focused ultrasound and has shown promise in treating small portions of canine OS followed by limb amputation. This study represents the first use of histotripsy to treat large volumes of canine OS, using fractionated treatments, without subsequent surgical resection. Our objective was to evaluate the safety and feasibility of treating large volumes of OS, following clinical outcomes after histotripsy. 9 dogs with suspected OS were treated with 1–5 histotripsy ablations, depending on tumor size, fractionated over 3 to 17 days. Pain, quality of life, and gait were followed over time, and MRI was used for pre-treatment planning and post-treatment monitoring. All dogs tolerated fractionated histotripsy treatments well, and the ablation zone was visible as a non-enhancing area on MRI matching the targeted location. There was a significant reduction in tumor contrast enhancement after completion of all histotripsy treatments and at the end of follow-up. Across all dogs with follow-up, there was a significant increase in pressure on the tumor-bearing limb during walking at the end of follow-up as compared to pre-treatment, indicating decreased pain. 4/6 dogs with follow-up showed a clinically significant decrease in pain. This study shows the promise of histotripsy as a non-invasive limb-sparing treatment for OS and advances the use of fractionated histotripsy treatments to ablate large and complicated tumors.

Indexed as

Bone NeoplasmsDog DiseasesHigh-Intensity Focused Ultrasound AblationOsteosarcomaAnimalsDogsFemaleMagnetic Resonance ImagingMaleTreatment OutcomeAblationCanineFocused ultrasoundFractionatedHistotripsyOsteosarcoma

Identifiers

PMID41872305
PMCPMC13153271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.